Showing results (201-210 of 213) with videos related to

Sort By:
Pageof 22
Cancer Research Communications|November 7, 2022
Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterationsRadhika A Patel, Ilsa Coleman, Martine P Roudier, et al.
Nature Biomedical Engineering|April 1, 2024
A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in miceShijie Cao, Erica Budina, Michal M Raczy, et al.
Plos One|May 1, 2013
Pleiotrophin gene therapy for peripheral ischemia: evaluation of full-length and truncated gene variantsQizhi Fang, Pamela Y Mok, Anila E Thomas, et al.
Gastrointestinal Cancer Research : GCR|March 19, 2013
Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortiumCelina S Ang, R Katie Kelley, Michael A Choti, et al.
Cell Reports. Medicine|July 8, 2025
Activity-attenuated serum albumin-fused interleukin-33 suppresses experimental autoimmune encephalomyelitisErica Budina, Joseph W Reda, Shijie Cao, et al.
JCI Insight|December 8, 2021
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerNavonil De Sarkar, Sayan Dasgupta, Payel Chatterjee, et al.
The Journal of Clinical Investigation|May 17, 2021
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growthMichael D Nyquist, Lisa S Ang, Alexandra Corella, et al.
The Medical Journal of Malaysia|July 31, 2025
Echocardiography detection rate of newly diagnosed valvular heart disease amongst patients 12 years old and beyond, referred for transthoracic echocardiography in tertiary care settingsT M Chen, J S Ang, P Josephine, et al.
JCI Insight|February 23, 2023
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancerErolcan Sayar, Radhika A Patel, Ilsa M Coleman, et al.
Breast Cancer Research and Treatment|September 23, 2021
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimensMing Shen Dai, Yin Hsun Feng, Shang Wen Chen, et al.
Pageof 22